Please login to the form below

Not currently logged in
Email:
Password:

HBV

This page shows the latest HBV news and features for those working in and with pharma, biotech and healthcare.

Gilead set to acquire hepatitis specialist MYR for €1.15bn

Gilead set to acquire hepatitis specialist MYR for €1.15bn

According to Gilead, at least 12 million people globally are currently co-infected with HDV and hepatitis B virus (HBV). ... Patients with HDV co-infection are at a higher risk of developing serious liver disease compared to those living with HBV

Latest news

More from news
Approximately 2 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    Success in our clinical programs for flu, HPV and HBV vaccines could help shine a light on vaccines: currently a therapeutic modality that saves more lives per year than almost any

  • Deal Watch October 2018

    Product / Technology. Deal Type. Headline. ($). Arrowhead/. Janssen (J&J). Development &commercialisation of ARO‐HBV, based on. ... the TRiM platform, for chronic HBV infection. Licence. $3.7B. Endocyte /. Novartis. Radiopharmaceuticals and drug

  • Pharma deals in April 2015 Pharma deals in April 2015

    These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with chronic hepatitis B virus (HBV) infection.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics